Baidu
map

Nature:代谢与肿瘤— —糖尿病治疗药物也可治肿瘤

2015-01-30 佚名 生物谷

近日,国际顶尖期刊nature刊登了来自美国安德森癌症研究中心Elsa R. Flores研究小组关于IAPP驱动代谢重编程抑制p53缺失的肿瘤生长的最新研究发现。 研究人员指出,在人类肿瘤中通常会发生TP53的改变,之前研究也已证明,在小鼠中重新激活TP53能够抑制肿瘤生长。但事实证明,重激活TP53这一策略非常难以实施,因此研究人员试图通过调控TP53同家族蛋白TP63和TP73寻找另外一条

近日,国际顶尖期刊nature刊登了来自美国安德森癌症研究中心Elsa R. Flores研究小组关于IAPP驱动代谢重编程抑制p53缺失的肿瘤生长的最新研究发现。

研究人员指出,在人类肿瘤中通常会发生TP53的改变,之前研究也已证明,在小鼠中重新激活TP53能够抑制肿瘤生长。但事实证明,重激活TP53这一策略非常难以实施,因此研究人员试图通过调控TP53同家族蛋白TP63和TP73寻找另外一条抑制肿瘤生长的策略。p63和p73的TA亚型在结构和功能上都与p53非常类似,但p63和p73的ΔN亚型(缺失酸性转激活结构域)通常在癌症中出现过表达,主要以p53,TA63和TA73的功能缺失形式抑制他们的抗肿瘤功能。p53家族蛋白能广泛影响细胞内各种进程发挥抑制肿瘤的功能,比如细胞凋亡和自噬,因此了解p53家族蛋白与各个细胞过程之间的相互作用对通过改变p53信号通路治疗肿瘤具有重要意义。
 
Avinashnarayan Venkatanarayan等研究人员通过p63或p73 ΔN亚型缺失发现这会导致细胞内代谢重编程,并且会通过上调IAPP抑制p53缺失的肿瘤生长。IAPP能够编码淀粉不溶素,并通过降钙素受体(CalcR)以及受体活性修饰蛋白3(RAMP3)抑制细胞糖酵解,诱导ROS产生和细胞凋亡。同时,研究人员还发现普兰林肽(目前用于治疗I型和II型糖尿病的药物)能够引起p53缺失的胸腺淋巴瘤的快速抑制。
 
综上所述,该文章发现p53同家族蛋白p63和p73的ΔN亚型缺失能够上调IAPP表达,驱动肿瘤细胞内代谢重编程,通过诱导ROS产生以及细胞凋亡过程抑制p53缺失的肿瘤生长,同时还发现普兰林肽在抑制胸腺淋巴瘤方面的新作用,这对开发治疗肿瘤新药有非常重要的意义。

原始出处

Venkatanarayan A1, Raulji P2, Norton W3, Chakravarti D1, Coarfa C4, Su X5, Sandur SK6, Ramirez MS7, Lee J7, Kingsley CV7, Sananikone EF1, Rajapakshe K4, Naff K3, Parker-Thornburg J8, Bankson JA7, Tsai KY9, Gunaratne PH10, Flores ER1.IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.Nature. 2015 Jan 29

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1989924, encodeId=163b19899245a, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sun Mar 15 05:39:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880475, encodeId=63b118804e550, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Feb 19 08:39:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921619, encodeId=e4941921619dc, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 20 16:39:00 CST 2015, time=2015-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20403, encodeId=7a9c2040384, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:49:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16275, encodeId=0a92162e536, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:08:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14889, encodeId=967a14889a1, content=双胍!, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jan 30 19:57:00 CST 2015, time=2015-01-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1989924, encodeId=163b19899245a, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sun Mar 15 05:39:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880475, encodeId=63b118804e550, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Feb 19 08:39:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921619, encodeId=e4941921619dc, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 20 16:39:00 CST 2015, time=2015-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20403, encodeId=7a9c2040384, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:49:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16275, encodeId=0a92162e536, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:08:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14889, encodeId=967a14889a1, content=双胍!, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jan 30 19:57:00 CST 2015, time=2015-01-30, status=1, ipAttribution=)]
    2015-02-19 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1989924, encodeId=163b19899245a, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sun Mar 15 05:39:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880475, encodeId=63b118804e550, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Feb 19 08:39:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921619, encodeId=e4941921619dc, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 20 16:39:00 CST 2015, time=2015-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20403, encodeId=7a9c2040384, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:49:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16275, encodeId=0a92162e536, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:08:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14889, encodeId=967a14889a1, content=双胍!, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jan 30 19:57:00 CST 2015, time=2015-01-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1989924, encodeId=163b19899245a, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sun Mar 15 05:39:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880475, encodeId=63b118804e550, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Feb 19 08:39:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921619, encodeId=e4941921619dc, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 20 16:39:00 CST 2015, time=2015-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20403, encodeId=7a9c2040384, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:49:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16275, encodeId=0a92162e536, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:08:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14889, encodeId=967a14889a1, content=双胍!, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jan 30 19:57:00 CST 2015, time=2015-01-30, status=1, ipAttribution=)]
    2015-04-11 x35042875

    AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1989924, encodeId=163b19899245a, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sun Mar 15 05:39:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880475, encodeId=63b118804e550, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Feb 19 08:39:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921619, encodeId=e4941921619dc, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 20 16:39:00 CST 2015, time=2015-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20403, encodeId=7a9c2040384, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:49:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16275, encodeId=0a92162e536, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:08:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14889, encodeId=967a14889a1, content=双胍!, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jan 30 19:57:00 CST 2015, time=2015-01-30, status=1, ipAttribution=)]
    2015-02-17 chinayinhan

    已阅

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1989924, encodeId=163b19899245a, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sun Mar 15 05:39:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880475, encodeId=63b118804e550, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Feb 19 08:39:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921619, encodeId=e4941921619dc, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 20 16:39:00 CST 2015, time=2015-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20403, encodeId=7a9c2040384, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:49:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16275, encodeId=0a92162e536, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:08:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14889, encodeId=967a14889a1, content=双胍!, beContent=null, objectType=article, channel=null, level=null, likeNumber=188, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jan 30 19:57:00 CST 2015, time=2015-01-30, status=1, ipAttribution=)]
    2015-01-30 lovetcm

    双胍!

    0

相关资讯

Science:ATR抑制药可靶向治疗依赖ALT的肿瘤

美国《科学》杂志近日发表一篇论文,介绍了一种全新的癌症靶向治疗方法,有可能遏制骨肉瘤、脑瘤以及某些胰腺肿瘤的生长,不过这种方法还有待通过临床研究来验证。 这项研究通过阻断癌细胞用以维持增殖能力的信号通路,来达到抑制几种侵袭性肿瘤生长的目的。发现可预示癌细胞弱点的遗传标记物,开发针对这些弱点的新药,是当前癌症研究的一个焦点。 论文共同通讯作者、马萨诸塞综合医院癌症中心科研副主任邹力告诉新华社记者

抑癌物佛波酯长期使用可促进肿瘤发生

蛋白激酶C(PKC)系统,该系统中的第二信使是磷脂肌醇,故又称为磷脂肌醇信号途径。PKC系统由三个成员组成:受体、G蛋白和效应物。Gq蛋白也是异源三体,其α亚基上具有GTP/GDP结合位点,作用方式与cAMP系统中的G蛋白完全相同。该系统的效应物是磷酸肌醇特异的磷脂酶C-β,此处的β表示一种异构体。在PKC系统信号转导途径中,膜受体与第一信使分子结合后,激活膜上Gp蛋白,然后Gq蛋白激活磷酸脂酶C

第7届亚洲肿瘤峰会会议通知

代表会议的主办方, 我们盛情邀请您来参加2015年4月10日至12日在中国上海国际会展中心举办的第7届亚洲肿瘤峰会和第11届肿瘤与转化研究组织年会。 病毒性肝炎专题峰会也将首次同时举行,此次峰会将聚集来自各个学科的专家,为共同研究、促进合作提供了独一无二的机会。 会议时间:2015年4月10-12日 会议地点:上海 会议日程下载:AOS2015_programme.pdf 我们同时邀请您

第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 第一轮征文通知

第十八届全国临床肿瘤学大会暨2015年CSCO学术年会拟定于2015年9月16日~9月20日在福建省厦门市国际会议展览中心召开。大会主题为“推动多学科协作,倡导科学化管理”,大会将秉承CSCO的根本宗旨,进一步促进国际、国内开展临床肿瘤学领域的学术交流和科技合作,鼓励支持临床研究和创新,提倡规范化综合治疗,积极推动学科发展。欢迎广大CSCO会员和临床肿瘤学工作者积极投稿,切磋实践经验和分享研究成果

“安全阴云”笼罩肿瘤免疫疗法领域

癌症,一直是全世界科学家试图征服的对象。为此,人们先后开发了化疗、放疗等手段用来杀灭肿瘤细胞。然而,这些治疗方案要么是“威力”不够,无法抑制肿瘤细胞的疯狂生长;要么是伤敌一千,自损八百。 随着科学家对免疫系统的了解,科学家们开始意识到人类自身的免疫系统或许是最终解决这一问题的最好武器。2014年生物医药研究领域开始掀起了一场肿瘤免疫疗法的研究热潮。这其中最为耀眼的当属CAR-T疗法和双特异性

Nat Commun:肿瘤研究新工具---特异性标记血管新生

血管为全身器官和组织运送氧气和营养物质,对机体组织的生长、再生、伤口愈合、组织修复以及胎儿生长大有益处,但同时也会成为感染导致的炎症扩散、肿瘤细胞入侵和转移的渠道。在原有毛细血管或微静脉的基础上通过血管内皮细胞的增殖和迁移,从已存在的血管处以出芽的方式产生新的毛细血管的,这一过程被称为血管新生(Angiogenesis)。血管新生是机体发育生长中的一个重要过程,在促血管新生因子和抑血管新生因子

Baidu
map
Baidu
map
Baidu
map